Adaptimmune Therapeutics plc ADAP
Set alert
0.05 0.00 0.00%
As of Nov 21, 9:30 AM ET
0.0425 Day range 0.0599
52-week range unavailable
- YTD
- -91.00%
- 1 year
- -93.42%
- Open
- 0.0425
- Prev close
- 0.0485
- Mkt cap
- 75.16M
- Vol
- 1.68M
- Avg vol
- 0
- EPS
- 0.00
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 0.0425
- High
- 0.0599
- Forward P/E
- -1.52
- Beta
- 2.25
- Short ratio
- 4.71
- Inst. own
- 60.27%
- Dividend
- 0.00
- Ex-div date
- 50-d avg
- 0.71418
- 200-d avg
- 1.03
- 1y target
- 2.27
3M chart
Signals (13)
| Name | Date | Ago |
|---|---|---|
| SMA: Bearish | Oct 20, 2025 | 1 year ago |
| SMA: Bearish | Oct 20, 2025 | 1 year ago |
| MACD: Sell Signal | Oct 20, 2025 | 1 year ago |
| RSI: Overbought | Oct 9, 2025 | 1 year ago |
| RSI: Overbought | Sep 22, 2025 | 1 year ago |
| SMA: Bullish | Sep 18, 2025 | 1 year ago |
| RSI: Overbought | Sep 18, 2025 | 1 year ago |
| SMA: Bullish | Sep 15, 2025 | 1 year ago |
| RSI: Oversold | Sep 5, 2025 | 1 year ago |
| MACD: Buy Signal | Aug 19, 2025 | 1 year ago |
| RSI: Oversold | Aug 19, 2025 | 1 year ago |
| RSI: Oversold | Aug 14, 2025 | 1 year ago |
| RSI: Oversold | Aug 12, 2025 | 1 year ago |
Analyst view
Consensus: none
Price target (mean) 2.27 +4573.5% upside
Now 0.0485
- Target (low)
- 1.00
- Target (mean)
- 2.27
- Target (high)
- 3.50
Ratings (0m) 9 6 buy · 2 hold · 1 sell
- Strong buy2
- Buy4
- Hold2
- Sell0
- Strong sell1
Recommendation trend
- This month 9
- 1 month ago 9
Earnings and revenue estimates
Consensus for the coming quarters and fiscal years
| Period | EPS estimate | Low – high | Year ago | EPS growth | Revenue estimate | Revenue growth | Analysts |
|---|---|---|---|---|---|---|---|
| Current quarter | -0.154 | -0.21 – -0.05 | -0.24 | +35.8% | 8.83M | +3721.5% | 3 |
| Next quarter | 0.00 | 0.00 – 0.00 | 0.00 | 0.0% | 6.30M | +10.9% | 0 |
| Current year | -0.142 | -0.20 – -0.04 | -0.6762 | +79.0% | 183.80M | +204.9% | 3 |
| Next year | -0.47433 | -0.593 – -0.37 | -0.142 | -234.0% | 39.90M | -78.3% | 3 |
Upgrades and downgrades
The latest rating changes
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Nov 27, 2024 | Mizuho | Maintained | Outperform | Outperform |
| Nov 19, 2024 | HC Wainwright & Co. | Reiterated | Buy | Buy |
| Nov 15, 2024 | Guggenheim | Maintained | Buy | Buy |
| Nov 14, 2024 | HC Wainwright & Co. | Maintained | Buy | Buy |
| Aug 13, 2024 | HC Wainwright & Co. | Reiterated | Buy | Buy |
| Aug 5, 2024 | HC Wainwright & Co. | Reiterated | Buy | Buy |
| Jul 30, 2024 | HC Wainwright & Co. | Initiated | — | Buy |
| May 30, 2024 | Scotiabank | Initiated | — | Sector Outperform |
| May 17, 2024 | Mizuho | Maintained | Buy | Buy |
| Aug 10, 2023 | Barclays | Maintained | Underweight | Underweight |
| Aug 10, 2023 | EF Hutton | Reiterated | Buy | Buy |
| Jun 5, 2023 | EF Hutton | Reiterated | Buy | Buy |
| Jun 2, 2023 | EF Hutton | Reiterated | — | Buy |
| May 26, 2023 | EF Hutton | Reiterated | — | Buy |
| Apr 17, 2023 | EF Hutton | Reiterated | — | Buy |
| Apr 11, 2023 | EF Hutton | Reiterated | — | Buy |
| Mar 6, 2023 | EF Hutton | Reiterated | — | Buy |
| Jan 5, 2023 | EF Hutton | Initiated | — | Buy |
| Jan 3, 2023 | Guggenheim | Upgrade | Neutral | Buy |
| Nov 14, 2022 | Wells Fargo | Maintained | — | Equal-Weight |
| Nov 9, 2022 | Mizuho | Upgrade | Neutral | Buy |
| Oct 4, 2022 | Wells Fargo | Maintained | — | Equal-Weight |
| May 9, 2022 | SVB Leerink | Maintained | — | Market Perform |
| Mar 15, 2022 | SVB Leerink | Maintained | — | Market Perform |
| Sep 22, 2021 | Wells Fargo | Maintained | — | Equal-Weight |
| Sep 13, 2021 | SVB Leerink | Maintained | — | Market Perform |
| Sep 7, 2021 | SVB Leerink | Maintained | — | Market Perform |
| Aug 10, 2021 | SVB Leerink | Maintained | — | Market Perform |
| May 28, 2021 | Barclays | Initiated | — | Underweight |
| Nov 5, 2020 | SVB Leerink | Maintained | — | Market Perform |